Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673136 | 0.80 | KDM4E (0.36) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21235185 | 0.78 | — | — | |
| SCHEMBL30648016 | 0.77 | EIF4A3 (0.37) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL32673963 | 0.77 | KDM4E (0.34) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4429156 | 0.76 | KDM4E (0.44) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21569525 | 0.73 | GRIN2D (0.44) | NR3C1PGR | |
| SCHEMBL1757881 | 0.72 | HRH4 (0.32) | CYP2A6KEAP1 | |
| SCHEMBL837013 | 0.72 | DAO (0.53) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL16600333 | 0.72 | PIP5K1C (0.34) | — | |
| SCHEMBL30310477 | 0.72 | EIF4A3 (0.61) | KDM4EALDH1A1HPGDEIF4A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3183005-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | Pharmakea, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2016028686-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | PHARMAKEA, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016028686-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | PHARMAKEA, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | KDM4E 4044/4885HTT 138/4885SMN1; SMN2 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.